Every fall, before open enrollment opens, your Medicare drug plan mails you an Annual Notice of Change. Most people skim it. This year, if you are in a standalone prescription drug plan rather than a Medicare Advantage plan with drug coverage, the premium line is worth a slower read, because a federal support that has been sitting underneath that number since 2025 is being switched off at the end of this year.
The subsidy has a name, and it has been under your premium since 2025
It is called the Part D Premium Stabilization Demonstration, and it exists because of arithmetic that went badly in 2024. The Inflation Reduction Act rebuilt the Part D benefit and moved a large share of drug costs off beneficiaries and onto the insurance companies running the plans. When standalone drug plans priced that risk for 2025, CMS concluded that the law’s own limits on premium increases would not be enough to hold the result down.
So the government paid to hold the line. For 2025 the demonstration cut $15 off the national base beneficiary premium for participating standalone plans, capped any single plan’s year-over-year total premium increase at $35, and narrowed the risk corridors that determine how much money a plan can lose. For 2026 the government dialed all three back. As the CMS fact sheet setting the 2026 parameters put it, the agency reduced the uniform base premium reduction from $15 to $10, raised the increase limit from $35 to $50, and eliminated the narrowed risk corridors, explicitly “facilitating the program’s return to operating under regular market conditions.”
Free retirement updates: A quiet rule change can shrink your Social Security or Medicare check, and no one warns you. The free Retirement Shield newsletter catches these early and tells you what to do. Get it free.
CMS says plan sponsors now have “sufficient experience”
The final step came on July 28, 2026, buried in a technical release about next year’s bids. CMS announced the conclusion of the demonstration and gave its reasoning in one sentence: bid analysis indicates that Part D plan sponsors “had sufficient experience under the redesigned Part D benefit to support their assumptions in developing the prescription drug plan bids.”
The translation is that after two years of real claims data, insurers are no longer guessing at what the redesigned benefit costs them, so the government does not intend to keep absorbing the guesswork. CMS will therefore “discontinue the demonstration at the end of CY 2026 to return the program to operating under traditional market conditions in CY 2027,” according to the agency’s own fact sheet. Nothing about the change affects Medicare Advantage plans that include drug coverage. The demonstration only ever applied to standalone prescription drug plans, which is exactly the population whose notice deserves the slower read.
Why $41.33 is not the number on your bill
The same July release sets the 2027 national base beneficiary premium at $41.33, up from $38.99 for 2026. It is a real figure and it is easy to misread, so it is worth being precise: CMS describes the base beneficiary premium as “the starting point for calculating a plan-specific basic Part D premium.” It is an input, not a bill. The premium you actually pay is set by your plan’s bid, its benefit design and the region you live in, and it can sit well above or below the base.
The base number does drive one thing you may pay directly. The Part D late enrollment penalty is calculated as 1 percent of the national base beneficiary premium for every full month you went without drug coverage after you were eligible, and it is added to your premium permanently. Medicare’s own explanation of drug plan costs uses the 2026 base of $38.99 to work the example. When the base rises, so does the penalty attached to it.
The 6 percent cap in the law covers a different number than the $50 cap did
Two separate ceilings have been at work here, and only one of them survives into 2027. The Inflation Reduction Act limits how fast the national base beneficiary premium can climb, capping the annual increase at 6 percent per year between 2024 and 2029. That statutory cap is still in force, and the move from $38.99 to $41.33 is a 6 percent increase, the maximum the law allows.
The $50 limit was different. It capped the increase in an individual plan’s total Part D premium from one year to the next, which is the number a member actually writes a check for. That cap was a parameter of the demonstration rather than a provision of the underlying law, and CMS says the demonstration ends with 2026. The distinction is the whole reason this story is about a driver rather than a dollar figure.
Nothing plan-specific exists until the September landscape files
Here is the part that responsible reporting has to leave open. As of today there is no such thing as a 2027 premium for your plan, because CMS has not published one. The agency says it will release the 2027 Medicare Advantage and Part D landscape “in mid-to-late September, once all offerings are finalized,” along with final average premiums. Until those files publish, any specific 2027 premium quoted to you for a specific plan is an estimate wearing a number’s clothing, and anyone selling you a plan on that basis is ahead of the data.
What the record does support is a sense of scale for what the demonstration was doing. The Government Accountability Office examined it and reported in February 2026 that without the program, the average monthly premium for people who stayed in their 2024 standalone plan would have nearly doubled in 2025, and 37 percent of those beneficiaries would have seen increases of more than $40 a month. With the demonstration running, the average standalone premium for beneficiaries not receiving the low-income subsidy went from $42 in 2024 to $43 in 2025. GAO put the cost of that stability at an estimated $9.8 billion across 2025 and 2026. That is the support being withdrawn, and September is when its absence stops being a policy question and becomes a premium.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
